Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorHammond, Robert
dc.contributor.authorKloprogge, Frank
dc.contributor.authorDella Pasqua, O.
dc.contributor.authorGillespie, Stephen Henry
dc.date.accessioned2022-09-09T08:30:19Z
dc.date.available2022-09-09T08:30:19Z
dc.date.issued2022-09-09
dc.identifier280558935
dc.identifier4b09af52-0887-432c-bb25-7cd2f701599b
dc.identifier.citationHammond , R , Kloprogge , F , Della Pasqua , O & Gillespie , S H 2022 , ' Implications of drug-induced phenotypical resistance : is isoniazid radicalizing  M. tuberculosis ? ' , Frontiers in Antibiotics , vol. 1 , 928365 . https://doi.org/10.3389/frabi.2022.928365en
dc.identifier.otherORCID: /0000-0001-6537-7712/work/118800051
dc.identifier.otherORCID: /0000-0003-3664-3641/work/157140941
dc.identifier.urihttps://hdl.handle.net/10023/25980
dc.descriptionFunding: This study was funded by a grant from the British Society for Antimicrobial Chemotherapy (GA2015-172R).en
dc.description.abstractBackground: Treatment duration is long and does not guarantee eradication of infection. Shorter treatment regimens are a critical research objective to improve uptake and reduce the risk of relapse and bacterial resistance. The explanation for the need to continue treatment after patients are culture negative remains elusive. We have previously shown that the presence of lipid inclusions in mycobacterial cells is associated with an increase in antibiotic resistance. Aim: We investigate the bactericidal effect of isoniazid and rifampicin and the expression of lipid inclusions and the associated phenotypic antibiotic resistance to a range of anti-tuberculosis agents in current use. Methods: Antibiotic killing effect for both M. tuberculosis and M. komossense were investigated by both hollow fiber bioreactor (HFS) studies and static time kill curve (STKC) experiments. Following STKC cultures were stained with resazurin, Sytox green and Nile red to establish their live/dead (resazurin positive/Sytox positive) and lipid inclusion status respectively. In addition, M. komossense was studied in the hollow fiber bioreactor model (HFS) and exposed to isoniazid (H) and rifampicin (R). The MIC of current antituberculosis agents for cells from the treated hollow fiber experiments were tested. Results: Antibiotic killing was similar for both species. For M. komossense; isoniazid was ineffective at the established MIC (1mg/L) in the hollow fiber bioreactor but rifampicin reduced the viable count rapidly at MIC (0.4mg/L). When the two drugs were combined at their respective MICs the killing effect was significant and greater than separately. Cells exposed to isoniazid (1x & 9x MIC) for 168 hours showed considerable numbers of recoverable viable cells when compared with a combination of 1x MIC R & H where there were no viable cells detectable. For both drugs the number of lipid body positive cells increased over time and this effect was most pronounced for isoniazid and was associated with phenotypic resistance to multiple anti-tuberculosis drugs. Conclusion: Our results showed that isoniazid is a potent stimulator of lipid body accumulation, culture persistence, and phenotypic resistance to multiple anti-tuberculosis drugs. These findings emphasise the importance of understanding mechanisms of drug-drug interactions and phenotypic resistance in regimen building.
dc.format.extent12
dc.format.extent2790584
dc.language.isoeng
dc.relation.ispartofFrontiers in Antibioticsen
dc.subjectTuberculosisen
dc.subjectAntibiotic resistanceen
dc.subjectDormancyen
dc.subjectPhenotypic resistanceen
dc.subjectDrug developmenten
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectNDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRMen
dc.titleImplications of drug-induced phenotypical resistance : is isoniazid radicalizing M. tuberculosis?en
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews. Centre for Biophotonicsen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.contributor.institutionUniversity of St Andrews. Global Health Implementation Groupen
dc.contributor.institutionUniversity of St Andrews. Gillespie Groupen
dc.contributor.institutionUniversity of St Andrews. Biomedical Sciences Research Complexen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doi10.3389/frabi.2022.928365
dc.description.statusPeer revieweden
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/frabi.2022.928365/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLEen


This item appears in the following Collection(s)

Show simple item record